Quijano, Julito C.

HRN: 22-69-64  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/05/2023
CO-AMOXICLAV 625MG (TAB)
03/05/2023
03/12/2023
PO
500 MG
BID
Abrasions
Waiting Final Action 

Indication:  ProphylaxisEmpiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: